Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

3.0K
3.0K
Cancer Therapies02:49

Cancer Therapies

10.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.3K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.3K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.6K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.6K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.0K
6.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Treatment Attrition From Surgery to Adjuvant Therapy in Stage IIB and IIIA Lung Adenocarcinoma: A National Cancer Database Analysis.

Clinical lung cancer·2026
Same author

Pre-operative Radiation for Resectable Retroperitoneal Sarcoma: Where are we With Risk-benefit Calculus?

Annals of surgery·2026
Same author

Response to Xu et al., "Letter to Editor 'Mohs micrographic surgery reduces the risk of reconstruction with positive margins, repeat surgeries, and time to definitive reconstruction compared to conventional excision of hand and foot melanomas: A retrospective cohort study'".

Journal of the American Academy of Dermatology·2026
Same author

Response-Based Immunotherapy in Melanoma: A New Paradigm.

Surgical oncology clinics of North America·2026
Same author

ASO Visual Abstract: Prognostic Value of Non-Nodal Regional Metastases in Predicting Sentinel Lymph Node Status in Cutaneous Melanoma: Multicenter Analysis of the Sentinel Lymph Node Working Group Database.

Annals of surgical oncology·2026
Same journal

Long-term quality of life after cytoreductive surgery and HIPEC: A survivorship analysis.

Surgical oncology·2026
Same journal

Comparative safety of postoperative HIPEC with recombinant mutant TNF-α versus paclitaxel for gastric cancer peritoneal metastasis: a randomized controlled trial.

Surgical oncology·2026
Same journal

Early postoperative hospital exposome stress, multisystem recovery trajectories, and long-term oncologic outcomes after curative colorectal cancer surgery.

Surgical oncology·2026
Same journal

Prognostic significance of age in adult primary intestinal diffuse large B-cell lymphoma: Insights from the SEER database.

Surgical oncology·2026
Same journal

Total neoadjuvant therapy versus standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer: A systematic review and meta-analysis of long-term outcomes.

Surgical oncology·2026
Same journal

Associations of latent profiles of resilience and fear of progression with discharge symptoms and postoperative frailty among patients undergoing lung resection: A longitudinal study.

Surgical oncology·2026
See all related articles

Related Experiment Video

Updated: Apr 5, 2026

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
11:15

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Published on: May 6, 2018

10.7K

Update for ASCO 2015 sarcoma sessions.

Giorgos Karakousis1

  • 1Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA.

Surgical Oncology
|August 24, 2015
PubMed
Summary
This summary is machine-generated.

This review covers recent advancements in soft tissue sarcoma (STS) treatment, including new therapies, local treatment efficacy, and the role of next-generation sequencing in managing advanced cancer.

Keywords:
ASCOSarcoma sessions

More Related Videos

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

19.8K
The In ovo CAM-assay as a Xenograft Model for Sarcoma
12:44

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

26.5K

Related Experiment Videos

Last Updated: Apr 5, 2026

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
11:15

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Published on: May 6, 2018

10.7K
Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

19.8K
The In ovo CAM-assay as a Xenograft Model for Sarcoma
12:44

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

26.5K

Area of Science:

  • Medical Oncology
  • Surgical Oncology
  • Genomics

Background:

  • Soft tissue sarcoma (STS) presents diverse clinical challenges, necessitating continuous research into effective treatment strategies.
  • The American Society for Clinical Oncology (ASCO) annual meeting features critical updates on sarcoma research.
  • Advanced STS requires novel therapeutic approaches and a deeper understanding of prognostic markers.

Purpose of the Study:

  • To summarize key findings from oral and poster presentations at the ASCO sarcoma sessions.
  • To highlight advancements in medical therapy, local treatment strategies, and molecular profiling for STS.
  • To provide a concise overview of relevant research for clinicians and researchers in the field.

Main Methods:

  • Review of select presentations from the ASCO sarcoma sessions.
  • Synthesis of information on new medical therapy regimens for advanced STS.
  • Analysis of research on local therapies for specific STS histologies.
  • Evaluation of studies on next-generation sequencing (NGS) for tumor and circulating tumor DNA (ctDNA).

Main Results:

  • Over 75 presentations addressed various aspects of STS.
  • Investigations explored novel systemic treatments for advanced disease.
  • Studies assessed the impact of aggressive local interventions on specific STS types.
  • Emerging data highlighted the prognostic and therapeutic potential of NGS and ctDNA analysis.

Conclusions:

  • Recent ASCO sessions showcased significant progress in understanding and treating STS.
  • Next-generation sequencing offers promising avenues for personalized STS management.
  • The reviewed research underscores the importance of multidisciplinary approaches in optimizing patient outcomes.